NASDAQ:CORT - Corcept Therapeutics Stock Price, Price Target & More

Corcept Therapeutics trades on the NASDAQ under the ticker symbol "CORT."

Corcept Therapeutics Incorporated (NASDAQ:CORT) posted its earnings results on Tuesday, May, 8th. The biotechnology company reported $0.19 EPS for the quarter, beating analysts' consensus estimates of $0.18 by $0.01. The biotechnology company had revenue of $57.66 million for the quarter, compared to the consensus estimate of $58.18 million. Corcept Therapeutics had a net margin of 75.05% and a return on equity of 46.78%. The company's revenue for the quarter was up 108.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.06 EPS. View Corcept Therapeutics' Earnings History.

Corcept Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Corcept Therapeutics.

4 equities research analysts have issued 1 year price objectives for Corcept Therapeutics' stock. Their predictions range from $20.00 to $32.00. On average, they anticipate Corcept Therapeutics' stock price to reach $28.00 in the next year. This suggests a possible upside of 115.4% from the stock's current price. View Analyst Ratings for Corcept Therapeutics.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Corcept Therapeutics include Catalent (CTLT), Ionis Pharmaceuticals (IONS), United Therapeutics (UTHR), FibroGen (FGEN), Loxo Oncology (LOXO), GALAPAGOS NV/S (GLPG), Agios Pharmaceuticals (AGIO), Ligand Pharmaceuticals (LGND), Dr.Reddy's Laboratories (RDY), Taro Pharmaceutical Industries (TARO), HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals (GWPH), Madrigal Pharmaceuticals (MDGL) and Array Biopharma (ARRY).

News headlines about CORT stock have trended somewhat negative recently, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Corcept Therapeutics earned a daily sentiment score of -0.02 on Accern's scale. They also gave news coverage about the biotechnology company an impact score of 47.17 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Corcept Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include AJ Wealth Strategies LLC (0.38%), Denali Advisors LLC (0.20%), Municipal Employees Retirement System of Michigan (0.02%) and Xact Kapitalforvaltning AB (0.02%). Company insiders that own Corcept Therapeutics stock include David L Mahoney, G Leonard Baker Jr, Gary Charles Robb, James N Wilson, Joseph K Belanoff, Patrick G Enright, Renee D Gala and Robert S Fishman. View Institutional Ownership Trends for Corcept Therapeutics.

CORT stock was sold by a variety of institutional investors in the last quarter, including Denali Advisors LLC and Municipal Employees Retirement System of Michigan. Company insiders that have sold Corcept Therapeutics company stock in the last year include G Leonard Baker Jr and Robert S Fishman. View Insider Buying and Selling for Corcept Therapeutics.

CORT stock was acquired by a variety of institutional investors in the last quarter, including AJ Wealth Strategies LLC and Xact Kapitalforvaltning AB. Company insiders that have bought Corcept Therapeutics stock in the last two years include Gary Charles Robb and Renee D Gala. View Insider Buying and Selling for Corcept Therapeutics.

Shares of CORT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CORT stock can currently be purchased for approximately $13.00.

Corcept Therapeutics has a market capitalization of $1.52 billion and generates $159.20 million in revenue each year. The biotechnology company earns $129.12 million in net income (profit) each year or $0.44 on an earnings per share basis. Corcept Therapeutics employs 136 workers across the globe.

Corcept Therapeutics' mailing address is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-327-3270 or via email at [email protected]